Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 18;4(2):100911. doi: 10.1016/j.xcrm.2022.100911

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Proteomic profiles of pleural fluid-derived organoids indicated drug resistance mechanisms

(A) PCA plot of the protein expression levels of different groups. The control group is shown in blue. The combination group, in which the LCOs were treated with both osimertinib and BLU-667, is shown in green. The groups treated with osimertinib (Osi) and BLU-667 alone are shown in purple and yellow, respectively.

(B) Volcano plots of differentially expressed proteins (DEPs) are shown for the osimertinib versus control group.

(C) Volcano plot of DEPs is shown for the BLU-667 versus control group.

(D) Volcano plot of DEPs is shown for the combo versus control group.

(E) Expression levels of the caspase family in osimertinib versus control (orange), BLU-667 versus control (blue), and combo versus control (light purple).

(F) An overview of the alteration of the signaling cascade of EGFR and RET; arrows indicate the trend of the expression of related proteins.

(G) Changes in the expression levels of key proteins among the osimertinib versus control, BLU-667 versus control, and combo versus control groups. See also Figure S6.